Non-anticoagulant sulfated or sulfonated synthetic polymers

A pharmaceutical composition comprising a therapeutically effective amount of a non-anticoagulant, non-saccharide, sulfonated/sulfated synthetic polymer (NASSP);

• and a pharmaceutically acceptable excipient, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

A composition for treating a subject in need of enhanced blood coagulation, comprising a non-anticoagulant, non-saccharide sulfonated/sulfated polymer, characterized in that a therapeutically effective amount of the composition is administered to said subject, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

A composition for inhibiting Tissue Factor Pathway Inhibitor (TFPI) activity in a subject, the composition comprising a non-anticoagulant, non-saccharide sulfonated/sulfated polymer, characterized in that an amount of the composition sufficient to inhibit the TFPI is administered to the subject, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

A composition for inhibiting TFPI activity in a biological sample comprising a sufficient amount of a non-anticoagulant, non-saccharide sulfonated/sulfated polymer to inhibit the TFPI activity, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.

An in vitro method of measuring acceleration of blood clotting by a non-anticoagulant, non-saccharide, sulfonated/sulfated polymer in a biological sample, the method comprising:

• a) combining the biological sample with a composition comprising the polymer, b) measuring the clotting time of the biological sample, c) comparing the clotting time of the biological sample to the clotting time of a corresponding biological sample not exposed to the polymer, wherein a decrease in the clotting time of the biological sample exposed to the polymer is indicative of a polymer that accelerates the clotting, wherein the polymer does not comprise —SO2—X group, where X represents a radical derived from arginine or an arginine derivative, bonded by its amino function —NH— to the radical —SO2—.